keyword
MENU ▼
Read by QxMD icon Read
search

cutaneous B cell lymphoma

keyword
https://www.readbyqxmd.com/read/28815289/-aggressive-primary-cutaneous-b-cell-lymphomas-and-novel-ebv-entities
#1
REVIEW
C Lamos, E Dippel
Primary cutaneous large B‑cell lymphomas (PCBLT), EBV-positive large B‑cell lymphomas, not otherwise specified (EBV+ DLBCL, NOS), and primary cutaneous intravascular large B‑cell lymphomas (PCIVLBL) are recognized as cutaneous lymphomas with intermediate to poor prognosis. Differentiation from indolent B‑cell lymphomas or other pathologies of the skin can be complex, both clinically and histologically, but vital for the outcome of the patient. The combination of immunotherapy and polychemotherapy regimens, such as R‑CHOP, has led to significant improvements in prognosis, especially in diffuse large B‑cell lymphomas...
August 16, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28802500/primary-cutaneous-b-cell-lymphomas
#2
REVIEW
Charity B Hope, Laura B Pincus
B-cell lymphomas represent approximately 20% to 25% of primary cutaneous lymphomas. Within this group, most cases (>99%) are encompassed by 3 diagnostic entities: primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. In this article, the authors present clinical, histopathologic, immunophenotypic, and molecular features of each of these entities and briefly discuss the rarer intravascular large B-cell lymphoma.
September 2017: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/28791248/an-unusual-presentation-of-chronic-lymphocytic-leukemia
#3
Dinesh Atwal, Mihir Raval, Belal Firwana, Jeanette Ramos, Appalanaidu Sasapu
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a B-cell lymphocytic neoplasm with indolent clinical course. If identified early, observation is opted. Many variables lead to the initiation of treatment. Authors describe a 62-year-old male presenting with shortness of breath and found to have white cell count of 1360 × 10(9)/L and subsequently was diagnosed with CLL/SLL. The patient received leukapheresis along with tumor lysis treatment and systemic chemotherapy with fludarabine, cyclophosphamide, and rituximab regimen...
July 2017: Avicenna Journal of Medicine
https://www.readbyqxmd.com/read/28770576/transformed-waldenstr%C3%A3-m-macroglobulinaemia-clinical-presentation-and-outcome-a-multi-institutional-retrospective-study-of-77-cases-from-the-french-innovative-leukemia-organization-filo
#4
Eric Durot, Cécile Tomowiak, Anne-Sophie Michallet, Jehan Dupuis, Bénédicte Hivert, Stéphane Leprêtre, Elise Toussaint, Sophie Godet, Fatiha Merabet, Eric Van Den Neste, Sarah Ivanoff, Xavier Roussel, Jean-Marc Zini, Caroline Regny, Richard Lemal, Laurent Sutton, Aurore Perrot, Katell Le Dû, Lukshe Kanagaratnam, Pierre Morel, Véronique Leblond, Alain Delmer
Histological transformation (HT) to diffuse large B-cell lymphoma (DLBCL) is a rare and poorly reported complication of Waldenström macroglobulinaemia (WM). We performed a retrospective study of 77 WM patients with biopsy-proven transformation to DLBCL. The median time from WM diagnosis to HT was 4·6 years and 16 patients (21%) had never been treated for WM. At HT, extranodal sites were observed in 91% of patients with a rather high incidence of central nervous system, cutaneous or testicular involvement...
August 2, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28766736/cutaneous-intravascular-nk-t-cell-lymphoma-with-peculiar-immunophenotype
#5
Victoria Alegría-Landa, Félix Manzarbeitia, Maria Gabriela Salvatierra Calderón, Luis Requena, Socorro María Rodríguez-Pinilla
Intravascular lymphoma (IVL) is a rare entity. Most cases are a variant of extranodal diffuse large B-cell lymphoma, and fewer than 10% of the published cases are of T-cell origin. Only intravascular B-cell lymphoma is recognized as a distinct entity in the most recent WHO classification of lymphoproliferative disorders. We describe a case of cutaneous NK/T IVL, with a cytotoxic immunophenotype and EBV positivity. However, our case was immunohistochemically negative not only for TCR-βF1 and TCR-γ (TCR-silent), but also for CD56, making it the first triple-negative NK/T IVL case to be described...
August 2, 2017: Histopathology
https://www.readbyqxmd.com/read/28766547/-breast-implant-associated-anaplastic-large-cell-lymphoma-a-case-report-and-a-review-of-literature
#6
N G Chernova, E E Zvonkov, A M Kovrigina, A B Sudarikov, D S Badmazhapova, N G Gabeeva, T N Obukhova, S R Karagyulyan, V G Savchenko
Breast implant-associated anaplastic large-cell lymphoma will be identified as a separate nosological entity in the 2017 adapted WHO classification due to differences in its clinical presentations, pathogenesis, and prognosis with those of nodal and cutaneous anaplastic large-cell lymphomas. The paper gives a review of the literature and describes the authors' own clinical case of common breast implant-associated anaplastic large-cell lymphoma involving breast tissue, axillary lymph nodes, anterior chest muscles, and bone marrow...
2017: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/28766120/-treatment-of-indolent-cutaneous-b%C3%A2-cell-lymphoma
#7
REVIEW
M Wobser
Primary cutaneous B‑cell lymphomas are rarely encountered and represent 25% of all cutaneous lymphomas. Follicular B‑cell lymphoma and marginal zone lymphoma belong to indolent subtypes which as a rule have no systemic dissemination and, thus, a mostly unchanged life expectancy. Therefore, skin-directed treatment options such as excision or radiotherapy are usually sufficient to control the disease. In contrast, cutaneous diffuse large B‑cell lymphoma and EBV-associated B‑cell lymphomas of the skin belong to more aggressive entities which demand a systemic first-line upfront therapy with R‑CHOP...
August 1, 2017: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/28748653/oral-bexarotene-for-post-transplant-cutaneous-t-cell-lymphoma
#8
Daniel J Lewis, Simo Huang, Madeleine Duvic
Organ transplant recipients receiving immunosuppression have an increased risk of developing post-transplant lymphoproliferative diseases (PTLDs). Traditionally, PTLDs refer to Epstein-Barr virus (EBV)-induced B-cell lymphoma. However, post-transplant T-cell lymphoma may also occur and tends to have a poorer response to reduced immunosuppressive therapy. As such, additional therapy is often needed for post-transplant T-cell lymphoma, including post-transplant cutaneous T-cell lymphoma (PT-CTCL). We present only the third case of PT-CTCL occurring after liver transplantation...
July 26, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28711152/functional-analysis-of-acquired-cd28-mutations-identified-in-cutaneous-t-cell-lymphoma
#9
Grzegorz B Gmyrek, Jeanette Pingel, Jaehyuk Choi, Jonathan M Green
CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function...
July 10, 2017: Cellular Immunology
https://www.readbyqxmd.com/read/28702966/possible-role-of-helicobacter-pylori-in-diseases-of-dermatological-interest
#10
C Guarneri, J Lotti, M Fioranelli, M G Roccia, T Lotti, F Guarneri
Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. pylori infection were suggested in diseases of dermatological interest such as chronic urticaria, rosacea, Henoch-Schoenleins purpura, idiopathic thrombocytopenic purpura, cutaneous and oral lichen planus, atopic dermatitis, recurrent aphthous stomatitis, systemic sclerosis, psoriasis, Sjögrens syndrome, Behçet's disease, pruritus, alopecia areata, primary cutaneous marginal zone B-cell lymphomas, vitiligo, chronic prurigo, multiformis, prurigo nodularis, leukocytoclastic vasculitis, prurigo pigmentosa, eczema nummulare, primary cutaneous MALT-type lymphoma, sublamina densa-type linear IgA bullous dermatosis, Sweet's syndrome, cutaneous T-cell pseudolymphoma and pemphigus vulgaris...
April 2017: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28700504/silent-presentation-of-multiple-metastasis-burkitt-lymphoma-in-a-child-a-case-report-and-review-of-the-literature
#11
REVIEW
Ingrith Miron, Lucian Miron, Vasile Valeriu Lupu, Ancuta Ignat
RATIONALE: The Burkitt lymphoma (BL) is a very aggressive B-cell non-Hodgkin's lymphoma. It accounts for 34% of lymphoma cases in children. PATIENT CONCERNS: We present the case of a 6-year-old boy diagnosed with BL, who presented multiple contrasting elements of the disease: silent symptomatology, without involvement of the bone marrow at first, but with multiorgan infiltration and a fast evolution, despite starting the treatment shortly after the symptoms appeared...
July 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28695331/vorinostat-and-mithramycin-a-in-combination-therapy-as-an-interesting-strategy-for-the-treatment-of-s%C3%A3-zary-t-lymphoma-a-transcriptomic-approach
#12
R Ragheb, G Venton, R Chelbi, N Bonnet, T Le Treut, V Ivanov, C Mercier, P Poulin, N Beaufils, J Gabert, P Suchon, P Rihet, B Loriod, B Kahn-Perlès, Régis T Costello
SAHA (vorinostat) is a histone deacetylase inhibitor approved by the USA Food and Drug Administration (FDA) for treating advanced refractory cutaneous T cell lymphomas. As SAHA alters the expression of many genes under control of the Sp1 transcription factor, we examined the effect of its association with the FDA-approved anticancer antibiotic Mithramycin A (MTR, plicamycin), a competitive inhibitor of Sp1 binding to DNA. Sézary syndrome (SS) cells, expanded ex vivo from peripheral blood mononuclear cells of 4 patients, were tested for their sensitivity to the drugs regarding cytotoxicity and differential responsive gene expression...
July 10, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28685851/risk-of-cutaneous-t-cell-lymphoma-in-patients-with-chronic-lymphocytic-leukemia-and-other-subtypes-of-non-hodgkin-lymphoma
#13
Timothy W Chang, Amy L Weaver, Tait D Shanafelt, Thomas M Habermann, Cooper C Wriston, James R Cerhan, Timothy G Call, Jerry D Brewer
BACKGROUND: Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy-related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B-cell lymphoma. Although cutaneous T-cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non-Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program...
July 7, 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28684330/spindle-cell-variant-of-primary-cutaneous-follicle-center-b-cell-lymphomas-are-germinal-center-b-cell-lymphomas-by-gene-expression-profiling-using-formalin-fixed-paraffin-embedded-specimen
#14
Ilske Oschlies, Christian W Kohler, Monika Szczepanowski, Karoline Koch, Artur Gontarewicz, Dieter Metze, Uwe Hillen, Julia Richter, Rainer Spang, Wolfram Klapper
No abstract text is available yet for this article.
July 3, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/28670978/a-novel-blk-induced-tumor-model
#15
David Leander Petersen, Jens Berthelsen, Andreas Willerslev-Olsen, Simon Fredholm, Sally Dabelsteen, Charlotte Menné Bonefeld, Carsten Geisler, Anders Woetmann
B-lymphoid tyrosine kinase (BLK) is a non-receptor tyrosine kinase belonging to the SRC family kinases. BLK is known to be functionally involved in B-cell receptor signaling and B-cell development. New evidence suggests that B-lymphoid tyrosine kinase is ectopically expressed and is a putative oncogene in cutaneous T-cell lymphoma and other T-cell malignancies. However, little is known about the role of BLK in lymphomagenesis, and the oncogenic function seems to depend on the cellular context. Importantly, BLK is also ectopically expressed in other hematological and multiple non-hematological malignancies including breast, kidney, and lung cancers, suggesting that BLK could be a new potential target for therapy...
July 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28648516/-mycosis-fungoides-in-a-heart-transplant-recipient
#16
Q Bodard, N Litrowski, D Carre, M Midhat, P Chenal, P Bravard
BACKGROUND: Skin cancer occurs frequently in organ transplant patients as a result of induced immunosuppression. Most cases involve carcinomas or B-cell lymphomas induced by the Epstein Barr virus (EBV). Cutaneous T-cell lymphomas remain rare. We report a case of cutaneous T-cell lymphoma of the mycosis fungoides type in a heart transplant recipient. PATIENTS AND METHODS: A 68-year-old man who had received a heart transplant 21years earlier and was being treated with tacrolimus, mycophenolate mofetil and prednisolone had been presenting a psoriasiform rash on his trunk, limbs and head for 4years...
June 22, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28638263/cutaneous-presentation-of-diffuse-large-b-cell-lymphoma
#17
Robin George Manappallil, Abhay Mani Martin, Neena Mampilly, Kunivayalil Sajeevan
No abstract text is available yet for this article.
June 2017: Eurasian Journal of Medicine
https://www.readbyqxmd.com/read/28631652/primary-cutaneous-large-b-cell-lymphoma-of-scalp-case-report-of-a-rare-variant
#18
Yasmeen Khatib, Madhura Dande, Richa D Patel, Meena Makhija
Primary cutaneous large B-cell lymphoma (Bcl) is defined as a lymphoma composed of large cells constituting more than 80% of the infiltrate and absence of extracutaneous involvement after staging investigations. In the new World Health Organization/European Organization for Research and Treatment of Cancer classification, cutaneous Bcls with large cells are of three types - primary cutaneous large Bcl leg type (PCLBCLLT), primary cutaneous follicle center lymphoma diffuse type (PCFCLDT), and primary cutaneous large Bcls other (PCLBCLO)...
April 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28614957/associated-hematolymphoid-malignancies-in-patients-with-lymphomatoid-papulosis-a-canadian-retrospective-study
#19
Mohanad AbuHilal, Scott Walsh, Neil Shear
BACKGROUND: Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. Although considered a benign disease, lymphomatoid papulosis has been associated potentially with an increased risk of secondary hematolymphoid malignancies. OBJECTIVE: The aim of this study was to assess the clinical characteristics and histologic subtypes of lymphomatoid papulosis, identify the prevalence and types of secondary hematolymphoid malignancies, and determine the potential risk factors for development of these hematolymphoid malignancies...
June 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28595473/cd4-cd26-lymphocytes-are-useful-to-assess-blood-involvement-and-define-b-ratings-in-cutaneous-t-cell-lymphoma
#20
Eric C Vonderheid, J Steve Hou
Bernengo et al. reported that >30% CD4(+)CD26(-) lymphocytes detect blood involvement in patients with mycosis fungoides (MF) and Sézary syndrome. In addition, the ISCL/EORTC suggested that this threshold might serve as a criterion for the B2 blood rating for staging. In this manuscript, we report our experience with measurement of CD4(+)CD26(-) and CD4(+)CD7(-) cells, Sézary cell counts, and aberrant T cells with diminished expression of CD2, CD3, or CD5 antigens. CD4(+)CD26(-) ≥30% occurred in 15 of 373 (4...
June 9, 2017: Leukemia & Lymphoma
keyword
keyword
85921
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"